Transcriptome profiling of serum exosomes by RNA-Seq reveals lipid metabolic changes as a potential biomarker for evaluation of roxadustat treatment of chronic kidney diseases
Molecular Omics · 2025
DOI: 10.1039/d4mo00025k ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Omics, 2025. Verfasst von Ru Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen 518020, Guangdong, China. echobbg@163.com. Hauptthemen laut MEDLINE: Exosomes, Renal Insufficiency, Chronic, Lipid Metabolism, Isoquinolines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The incidence of chronic kidney disease (CKD) is increasing globally; however, effective preventive and therapeutic strategies are currently limited. Roxadustat is being clinically used to treat renal anemia in CKD patients to reduce anemia-related complications and improve patients' life quality. Exosomes are small vesicles carrying important information that contribute to cell-to-cell communication and are present in various body fluids. However, little is known about the role of serum exosomes and their association with CKD after roxadustat treatment. Next-generation sequencing approaches have revealed that exosomes are enriched in noncoding RNAs and thus exhibit great potential as sensitive nucleic acid biomarkers in various human diseases. In this study, we aimed to identify the changed mRNAs–lncRNAs after roxadustat treatment as novel biomarkers for assessing the efficiency of the treatment. Through our study using RNA-seq data, we identified 957 mRNAs (626 upregulated and 331 downregulated after roxadustat treatment) and 914 lncRNAs (444 upregulated and 470 downregulated) derived from exosomes that were significantly changed, which was highly correlated to lipid metabolism. Our analysis through whole transcriptome profiling of exosome RNAs encompasses an identified differentially expressed mRNA–lncRNA regulatory axis in a larger patient cohort for the validation of suitable biomarkers for assessing CKD after roxadustat treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen 518020, Guangdong, China. echobbg@163.com.
- Department of Nephrology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, Guangdong, Chi…
Zitieren
APA
Zhou, R., Zhen, Y., Ma, H., Wang, Z., Liu, L., Zhang, X., & Guo, B. (2025). Transcriptome profiling of serum exosomes by RNA-Seq reveals lipid metabolic changes as a potential biomarker for evaluation of roxadustat treatment of chronic kidney diseases. Molecular Omics. https://doi.org/10.1039/d4mo00025k
Vancouver
Zhou R, Zhen Y, Ma H, Wang Z, Liu L, Zhang X, et al. Transcriptome profiling of serum exosomes by RNA-Seq reveals lipid metabolic changes as a potential biomarker for evaluation of roxadustat treatment of chronic kidney diseases. Molecular Omics. 2025. doi:10.1039/d4mo00025k
BibTeX
@article{Zhou2025,
author = {Zhou, Ru and Zhen, YaXuan and Ma, Hualin and Wang, Zhen and Liu, LiXia and Zhang, Xinzhou and Guo, Baochun},
title = {Transcriptome profiling of serum exosomes by RNA-Seq reveals lipid metabolic changes as a potential biomarker for evaluation of roxadustat treatment of chronic kidney diseases},
journal = {Molecular Omics},
year = {2025},
doi = {10.1039/d4mo00025k}
}
EUVIMED